Effect of Previous Interferon Treatment on Outcome After Curative Treatment for Hepatitis C Virus-related Hepatocellular Carcinoma

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2011 Oct 13

PMID 21989822

Citations 11

Authors

Hirokazu Miyatake

Yoshiyuki Kobayashi

Yoshiaki Iwasaki

Shin-Ichiro Nakamura

Hideki Ohnishi

Kenji Kuwaki

Junichi Toshimori

Hiroaki Hagihara

Kazuhiro Nouso

Kazuhide Yamamoto

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Treatment of chronic hepatitis C virus (HCV) infection with interferon (IFN) prevents the development of hepatocellular carcinoma (HCC). The purpose of this study was to clarify the effect of previous IFN treatment before the development of HCC on recurrence and survival in HCV-related HCC patients.

Methods: Three hundred ninety-five patients who underwent curative treatment for HCV-related HCC were enrolled. Of these, 124 had received IFN treatment before the development of HCC (17 achieved sustained virological response [SVR group] and 107 did not [non-SVR group]), whereas 271 patients had never received IFN treatment (IFN-untreated group). The first and second recurrence and survival rates in these patient groups were statistically analyzed.

Results: The first HCC recurrence rate was similar among patient groups. In contrast, the second HCC recurrence rate was significantly lower in the SVR group than in the non-SVR group (p = 0.003) and the IFN-untreated group (p = 0.006). In multivariate analysis, platelet count (p = 0.033) and number of tumors (p = 0.001) were associated with the first HCC recurrence, while SVR (p = 0.002) was the only factor associated with the second HCC recurrence. The survival rate was higher in the SVR group than in non-SVR and IFN-untreated groups, and SVR to previous IFN treatment was an independent factor associated with better survival (p < 0.001).

Conclusions: SVR to previous IFN treatment before the development of HCV-related HCC was associated with lower risk of the second recurrence of HCC and better survival.

Citing Articles

Impact of Thrombocytopenia on Survival in Patients with Hepatocellular Carcinoma: Updated Meta-Analysis and Systematic Review.

Kraj L, Chmiel P, Gryziak M, Grabowska-Derlatka L, Szymanski L, Wysokinska E Cancers (Basel). 2024; 16(7).

PMID: 38610973 PMC: 11011012. DOI: 10.3390/cancers16071293.

Timing of DAA Initiation After Curative Treatment and Its Relationship with the Recurrence of HCV-Related HCC.

Gao X, Zhan M, Wang L, Ding Y, Niu J J Hepatocell Carcinoma. 2020; 7:347-360.

PMID: 33299823 PMC: 7720283. DOI: 10.2147/JHC.S279657.

Direct-acting antivirals improve survival and recurrence rates after treatment of hepatocellular carcinoma within the Milan criteria.

Ochi H, Hiraoka A, Hirooka M, Koizumi Y, Amano M, Azemoto N J Gastroenterol. 2020; 56(1):90-100.

PMID: 33278003 PMC: 7819935. DOI: 10.1007/s00535-020-01747-y.

Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis.

Miuma S, Miyamoto J, Taura N, Fukushima M, Sasaki R, Haraguchi M Intern Med. 2020; 59(7):901-907.

PMID: 32238660 PMC: 7184089. DOI: 10.2169/internalmedicine.3382-19.

Effect of achieving sustained virological response before hepatitis C virus-related hepatocellular carcinoma occurrence on survival and recurrence after curative surgical microwave ablation.

Ryu T, Takami Y, Wada Y, Tateishi M, Matsushima H, Yoshitomi M Hepatol Int. 2018; 12(2):149-157.

PMID: 29488056 DOI: 10.1007/s12072-018-9851-4.

References

Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T . Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2002; 24(4):404-412. DOI: 10.1016/s1386-6346(02)00147-x. View

Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T . Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993; 328(25):1797-801. DOI: 10.1056/NEJM199306243282501. View

Lee M, Mueller P, Dawson S, Gazelle S, Hahn P, Goldberg M . Percutaneous ethanol injection for the treatment of hepatic tumors: indications, mechanism of action, technique, and efficacy. AJR Am J Roentgenol. 1995; 164(1):215-20. DOI: 10.2214/ajr.164.1.7998542. View

Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M . Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med. 1991; 325(10):675-80. DOI: 10.1056/NEJM199109053251002. View

Tanaka K, Hirohata T, Koga S, Sugimachi K, Kanematsu T, Ohryohji F . Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res. 1991; 51(11):2842-7. View

Livraghi T, Goldberg S, Lazzaroni S, Meloni F, Solbiati L, Gazelle G . Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999; 210(3):655-61. DOI: 10.1148/radiology.210.3.r99fe40655. View

Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H . Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002; 89(4):418-22. DOI: 10.1046/j.0007-1323.2001.02054.x. View

Imai Y, Tamura S, Tanaka H, Hiramatsu N, Kiso S, Doi Y . Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders. J Viral Hepat. 2009; 17(3):185-91. DOI: 10.1111/j.1365-2893.2009.01163.x. View

Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K . The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med. 1998; 4(9):1065-7. DOI: 10.1038/2053. View

10.

Breitenstein S, Dimitroulis D, Petrowsky H, Puhan M, Mullhaupt B, Clavien P . Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009; 96(9):975-81. DOI: 10.1002/bjs.6731. View

11.

. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet. 1999; 351(9115):1535-9. View

12.

Lam V, Ng K, Chok K, Cheung T, Yuen J, Tung H . Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg. 2008; 207(1):20-9. DOI: 10.1016/j.jamcollsurg.2008.01.020. View

13.

Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T . Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology. 1995; 22(4 Pt 1):1027-33. DOI: 10.1016/0270-9139(95)90605-3. View

14.

Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S . Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003; 138(4):299-306. DOI: 10.7326/0003-4819-138-4-200302180-00008. View

15.

Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S . Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998; 27(5):1394-402. DOI: 10.1002/hep.510270529. View

16.

Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O . Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000; 132(7):517-24. DOI: 10.7326/0003-4819-132-7-200004040-00002. View

17.

Uenishi T, Nishiguchi S, Tamori A, Yamamoto T, Shuto T, Hirohashi K . Influence of interferon therapy on outcome after surgery for hepatitis C virus-related hepatocellular carcinoma. Hepatol Res. 2006; 36(3):195-200. DOI: 10.1016/j.hepres.2006.07.011. View

18.

Ikeda K, Arase Y, Kobayashi M, Saitoh S, Someya T, Hosaka T . Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis. J Gastroenterol. 2003; 38(9):865-76. DOI: 10.1007/s00535-003-1163-2. View

19.

Belghiti J, Panis Y, Farges O, Benhamou J, Fekete F . Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg. 1991; 214(2):114-7. PMC: 1358509. DOI: 10.1097/00000658-199108000-00004. View

20.

Farmer D, Rosove M, Shaked A, Busuttil R . Current treatment modalities for hepatocellular carcinoma. Ann Surg. 1994; 219(3):236-47. PMC: 1243131. DOI: 10.1097/00000658-199403000-00003. View